Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Path dependence in immunisation programmes and how implementation science can guide system reform towards self-reliance in Africa.

BMJ public health·2026
Same author

Addressing the silent epidemic of antimicrobial resistance in the African region: a scoping review of evidence gaps and research considerations.

BMJ public health·2026
Same author

African Vaccination Week as a catalyst for integrated services and immunisation equity: synthesis of implementation insights from countries in the WHO African Region.

BMJ public health·2026
Same author

Measuring vaccine effects on antibiotic use and antimicrobial resistance in low and middle-income countries: A scoping review of methodological approaches, data sources, metrics, and limitations.

PLOS global public health·2026
Same author

Breaking the glass ceiling: concretising learning systems for vaccination by 2030 and beyond in Africa.

BMJ public health·2026
Same author

Celebrating the 50th anniversary of the essential programme on immunization and paving the way for the future of immunization in Central Africa.

Public health in practice (Oxford, England)·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Beta-blockers for hypertension.

Charles Shey Wiysonge1, Hazel A Bradley, Jimmy Volmink

  • 1Division of Medical Microbiology & Institute of Infectious Disease andMolecular Medicine, University of Cape Town, Observatory,South Africa. charles.wiysonge@uct.ac.za

The Cochrane Database of Systematic Reviews
|November 16, 2012
PubMed
Summary
This summary is machine-generated.

Beta-blockers offer modest cardiovascular benefits for hypertension but are less effective than other drugs. Evidence quality is low, necessitating further research into specific beta-blocker types and patient groups.

Related Experiment Videos

Last Updated: May 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • This review updates a 2007 Cochrane Review on beta-blockade as first-line hypertension therapy.
  • Assesses the role of beta-blockers in managing high blood pressure.

Purpose of the Study:

  • To quantify the effectiveness and safety of beta-blockers for hypertension.
  • Evaluate impact on morbidity and mortality endpoints in adult patients.

Main Methods:

  • Systematic review of 13 randomized controlled trials (RCTs) comparing beta-blockers to placebo or other antihypertensives.
  • Data synthesized using risk ratios (RR) and confidence intervals (CI); fixed- or random-effects models applied.
  • Included trials of at least one-year duration with adult hypertension patients.

Main Results:

  • Beta-blockers showed no significant difference in total mortality versus placebo, diuretics, or RAS inhibitors, but higher mortality than CCBs.
  • Total cardiovascular disease (CVD) was lower than placebo, mainly due to reduced stroke incidence.
  • Beta-blockers were associated with worse CVD outcomes than CCBs and increased stroke risk compared to CCBs and RAS inhibitors.

Conclusions:

  • Initiating hypertension treatment with beta-blockers yields modest CVD reductions but no significant mortality benefits.
  • Beta-blocker efficacy is inferior to other antihypertensive drug classes.
  • Low GRADE quality of evidence suggests potential for substantial differences in true effects; further high-quality research is recommended.